# AMISH : Aprovel for Management of Isolated Systolic Hypertension

> **NCT00264212** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 436 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** irbesartan and irbesartan-hydrochlorothiazide

## Key facts

- **NCT ID:** NCT00264212
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 436 (—)
- **Last updated:** 2007-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264212, "AMISH : Aprovel for Management of Isolated Systolic Hypertension". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00264212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*